GlassScriptPhysician profile
Ibrahim H Azar
NPI 1427408327
$10,616.21
in general payments reported to CMS, 2019-2025
11 companies · $3,594 in 2025
The $3,594 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $272 · 2023: $1,877 · 2024: $4,874 · 2025: $3,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,826 · Food and Beverage: $513 · Travel and Lodging: $5.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,826.25 |
| Food and Beverage | $512.95 |
| Travel and Lodging | $5.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,705.55 | 2023-2025 | Imjudo, Imfinzi, Tagrisso |
| Abbvie INC. | $2,400.00 | 2025 | |
| Genmab U.S., INC. | $1,970.46 | 2024 | Epkinly |
| Janssen Biotech, INC. | $1,080.00 | 2025 | Rybrevant |
| Inspire Medical Systems, INC. | $138.06 | 2024 | Inspire |
| Incyte Corporation | $117.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.11 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $31.89 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $28.47 | 2023 | Imbruvica |
| Gilead Sciences, INC. | $22.02 | 2023 | |
| Daiichi Sankyo INC. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Azar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.